Astria Therapeutics, Inc. (ATXS) DCF Valuation

Astria Therapeutics, Inc. (ATXS) Valoración de DCF

US | Healthcare | Biotechnology | NASDAQ
Astria Therapeutics, Inc. (ATXS) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Astria Therapeutics, Inc. (ATXS) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Ingementista para su precisión, nuestra calculadora ATXS DCF le permite evaluar la valoración de Astria Therapeutics, Inc. utilizando datos financieros del mundo real al tiempo que ofrece una flexibilidad completa para modificar todos los parámetros esenciales para mejorar las proyecciones.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -26.3 -37.4 -195.0 -53.5 -83.0 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .0 .0 -164.6 .2 -15.2 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -26.3 -37.5 -30.4 -53.7 -67.8 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 36.2 44.9 125.5 226.4 246.5 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 1.2 1.5 1.6 .8 1.5 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 -.1 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -26.2 -37.2 -4.7 -52.0 -67.8 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -25.0 -36.9 -169.3 -52.6 -82.3 -1.5 .0 .0 .0 .0
WACC, % 7.82 7.82 7.81 7.82 7.82 7.82 7.82 7.82 7.82 7.82
PV UFCF
SUM PV UFCF -1.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt -175
Equity Value 174
Diluted Shares Outstanding, MM 30
Equity Value Per Share 5.77

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real ATXS financials.
  • Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe how your inputs affect Astria Therapeutics' valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and simplicity, complete with step-by-step instructions.

Key Features

  • Customizable Clinical Parameters: Adjust essential inputs like patient enrollment rates, treatment efficacy, and cost of goods sold.
  • Instant Valuation Metrics: Quickly calculates intrinsic value, NPV, and other key financial indicators.
  • High-Precision Analytics: Leverages Astria Therapeutics' real-world data for accurate valuation results.
  • Streamlined Scenario Testing: Easily evaluate various hypotheses and analyze their impacts.
  • Efficiency Booster: Avoid the hassle of creating intricate valuation models from the ground up.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based ATXS DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional variables.
  3. Instant Calculations: The model will automatically refresh to display Astria Therapeutics’ intrinsic value.
  4. Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
  5. Analyze and Decide: Utilize the findings to inform your investment or financial strategy.

Why Choose Astria Therapeutics' Calculator?

  • Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses all in one convenient package.
  • Customizable Inputs: Modify yellow-highlighted cells to explore different scenarios.
  • Detailed Insights: Automatically computes the intrinsic value and Net Present Value for Astria Therapeutics (ATXS).
  • Preloaded Data: Includes historical and forecasted data to provide accurate starting points.
  • Professional Quality: Perfect for financial analysts, investors, and business consultants focused on the biotech sector.

Who Should Use This Product?

  • Investors: Evaluate Astria Therapeutics, Inc.'s (ATXS) market potential before making investment decisions.
  • CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts for ATXS.
  • Startup Founders: Discover the valuation strategies of established biotech firms like Astria Therapeutics.
  • Consultants: Provide comprehensive valuation analyses and reports for clients interested in biotech investments.
  • Students and Educators: Utilize current data to learn and teach valuation methods in the context of the biotech industry.

What the Template Contains

  • Pre-Filled DCF Model: Astria Therapeutics’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Astria Therapeutics’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.